Microbial Manufacturing Platform For Non-Platform Proteins

By Dr. Cécile Brocard, Head Downstream Development

This content was created by Boehringer Ingelheim BioXcellence™

This whitepaper presents CASPON® Technology, an innovative proprietary platform developed by Boehringer Ingelheim for the manufacturing of recombinant proteins. This cutting-edge technology facilitates a platform approach to produce non-platform proteins expressed in microbial systems, effectively overcoming the challenges and limitations associated with existing tag-based systems in bioprocess development. CASPON® Technology offers a cost-effective and efficient solution that streamlines the entire process of development, minimizing complexity and ensuring a seamless transition from research to large-scale manufacturing.

By optimizing the manufacturing workflow, CASPON® Technology not only enhances productivity but also improves consistency and quality in protein production. Additionally, its versatility opens the door for a range of further applications, making it a significant advancement in the biopharmaceutical sector. As the industry continues to evolve, CASPON® Technology positions itself as a transformative tool that addresses current needs while paving the way for future innovations in recombinant protein manufacturing.